

# **Surgical treatment for cutaneous B-cell lymphoma**

## **Introduction**

Cutaneous primary B lymphomas (LBPCs) are B-cell non-Hodgkin's lymphomas, exclusively affecting the skin, with no evidence of systemic involvement.


There are no randomized studies for the treatment of indolent primary cutaneous B lymphomas (LBCPIs), marginal zone and centrofollicular lymphomas.

When localized, low-dose radiotherapy, surgery, or intralesional infiltration of corticosteroids or rituximab are chosen. Clinical follow-up, multi-field radiotherapy, or rituximab may be indicated in patients with multiple lesions.

We report two cases of patients with marginal zone LBPC without evidence of systemic involvement, who were successfully submitted to surgical treatment.

## **Case reports**

A 60-year-old woman was followed up for marginal area LBPC with papulonodular lesions on the face, unresponsive with methotrexate and doxycycline cycles. She underwent superficial radiotherapy with 36 Gy fractionated doses of 2 Gy, with good response. The patient presented an erythematous, moist, infiltrated plaque measuring 2.0 x 1.5 cm in the right temporal region, which was also refractory to topical and infiltrative corticosteroid therapy. Excision with a 5-mm margin and reconstruction with an advancement flap were chosen (Figure). The anatomopathological examination revealed dermal-hypodermic nodular lymphocytic infiltration with an epicenter in the reticular dermis. Immunohistochemistry showed positive CD20 and PAX-5 lymphocytes, with inconclusive BCL2 and BCL6. Free surgical margins. After 26 months of follow-up, the patient remained without tumor recurrence and good cosmetic result.



Legend: (A) Nodule with 2.0 x 1.5 centimeters in the right temporal region, compatible with cutaneous marginal zone B-cell lymphoma. (B) Surgical marking with a 5 millimeters margin. (C) Reconstruction with an advancement flap. (D) Late post-operative period of 2 years.

The second patient, a 57-year-old woman diagnosed with marginal zone LBPC with a 1.5 x 1.5 cm nodule on her left arm. Histology showed nodular lymphocytic infiltration in the dermis, with about 60% of B lymphocytes, which expressed CD20 and BCL2, absence of CD10 and BCL6 expression and presence of lymphoplasmacytoid cells in the periphery of some of the lymphoid aggregates, with a predominance of Kappa expression over Lambda (>10:1). With a single lesion, surgical excision with a margin of 5 mm and primary closure was chosen. Final anatomopathological examination showed free margins and, after 5 years, the patient did not present recurrence.

## Discussion

Due to the rarity of the disease, there is a lack of randomized clinical studies between the therapeutic modalities. The recommendations are based on a series of cases and consensus, with little information on surgical margins, ideal margin size and recurrence.

In a study conducted by Servitje *et al.*, 2013, with patients with marginal zone LBPC, there was no difference in the rate of relapse or disease-free survival between groups treated with surgery, radiotherapy, or surgery and radiotherapy.

Parbhakar and Cin retrospectively analyzed 25 patients with indolent LBPC: 16 treated with low-dose radiotherapy (30-40 Gy) and nine treated with surgical excision with a 5 mm safety margin. Acute radiodermatitis and chronic ulcer at the irradiated site were reported complications.

Surgical treatment is a valid option in patients with single, indolent lesions, with lower cost and fewer side effects. Based on the previous studies described, the authors used the 5 mm safety margin. Long-term follow-up of these patients is recommended.

## References

Hamilton SN, Wai ES, Tan K, Alexander C, Gascoyne RD, Connors JM. Treatment and outcomes in patients with primary cutaneous B-cell lymphoma: the BC Cancer Agency experience. *Int J Radiat Oncol Biol Phys.* 2013 Nov 15;87(4):719-25.

Ohtsuka M, Hamada T, Miyagaki T, Shimauchi T, Yonekura K, Kiyohara E, Fujita H, Izutsu K, Okuma K, Kawai K, Koga H, Sugaya M. Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020. *J Dermatol.* 2021 Feb;48(2):e49-e71.

Krenitsky A, Klager S, Hatch L, Sarriera-Lazaro C, Chen PL, Seminario-Vidal L. Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas. *Am J Clin Dermatol.* 2022 Sep;23(5):689-706.

Parbhakar S, Cin AD. Primary cutaneous B-cell lymphoma: Role of surgery. *Can J Plast Surg.* 2011 Summer;19(2):e12-4

Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, Dummer R, Duvic M, Hoppe RT, Pimpinelli N, Rosen ST, Vermeer MH, Whittaker S, Willemze R; European Organization for Research and Treatment of Cancer; International Society for Cutaneous Lymphoma. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. *Blood.* 2008 Sep 1;112(5):1600-9.

Lang CCV, Ramelyte E, Dummer R. Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma. *Front Oncol.* 2020 Aug 7;10:1163.

Servitje O, Muniesa C, Benavente Y, Monsálvez V, Garcia-Muret MP, Gallardo F, et al. Primary cutaneous marginal zone B-cell lymphoma: Response to treatment and disease-free survival in a series of 137 patients. *J Am Acad Dermatol.* 2013;69(3):357-65.